2
Jan
2019
Tag: pharmaceuticals
14
Nov
2018
Bionest
A Crowded Field for Migraine Therapies, Where Recently There Were None
Back in March, when we first wrote about migraine drug development, there were no approved therapies addressing the underlying mechanisms of these painful, sometimes chronic, headaches — the most prevalent neurological disorder worldwide. Now, three such drugs have reached the market. The three drugs — Aimovig (erenumab) from Amgen/Novartis, Ajovy (fremanezumab) from Teva Pharmaceuticals,...
23
Jul
2018
Bionest
Analysts’ Predictions on Top 10 Best Selling Drugs in 2024 — And Our Take
Market analyst firm Evaluate released their annual report, “EvaluatePharma World Preview 2018: Outlook to 2024,” last month. The report predicts that worldwide prescription drug sales will grow to over $1.2 trillion over the next six years. Novartis is projected to be 2024’s leading prescription drug company with $53.2 billion in overall sales, followed by Pfizer...
11
Jun
2018
Bionest
Embryonic Stem Cell Technology and FDA
Stem cell research has elicited both excitement and controversy since its earliest days. Hematopoietic stem cell transplants have been employed for some time in the treatment of certain blood cancers. More recently, researchers have reported clinical successes in using bone marrow transplants to treat sickle cell disease as well as multiple sclerosis, where bone marrow...
29
May
2018
Bionest
The First Cannabis-Derived Drug Heads for FDA Approval
A new treatment for two particularly severe forms of epilepsy is on track to become the first cannabis-derived drug to gain approval from the U.S. Food and Drug Administration (FDA). On April 19, an FDA advisory panel unanimously recommended the approval of Epidiolex (cannabidiol, also known as CBD), under development by British pharmaceutical company GW...
24
May
2018
Bionest
Hot Topics in Neurology at AAN
We have been thinking for some time about the importance of biomarkers in both drug discovery and clinical medicine as they relate to Alzheimer’s (and our In Vivo publication also addresses this topic in depth). At the recent American Academy of Neurology (AAN) conference, there was also widespread interest in this topic, spurred in part...
21
May
2018
Bionest
Anticipating ASCO
We always greatly anticipate the scientific and educational sessions presented at the American Society of Clinical Oncology (ASCO) annual meeting, this year being held in Chicago from June 1-5. The meeting is the largest of its kind focused on cancer, attracting more than 30,000 oncology professionals from around the world to discuss ”state-of-the-art treatment modalities, new therapies,...
14
May
2018
Bionest
New Gains in Frontline Non-Small Cell Lung Cancer
Each spring, those of us who watch the oncology space turn our attention to two big U.S. meetings for the latest research news: the American Association of Cancer Research (AACR) annual scientific meeting, held in April, and the American Society of Clinical Oncology (ASCO), which will take place in June. AACR previously focused primarily on...
7
May
2018
Bionest
New Contender in Race to Develop Allogeneic CAR-T Treatments
Just months after negotiating the sale of autologous CAR-T pioneer Kite Pharma to Gilead for $11.9 billion, two of the executives who led Kite to success are back with a new company, a clinical-stage asset, and a portfolio of 16 preclinical therapeutic candidates, as well as substantial financing. This time, the focus is the development...
17
Apr
2018